FOXP3 and melanoma: To establish the method, we used a data set of PBMCs from melanoma patients and healthy controls (HCs), which previously identified that total FOXP3+ T cells increased in melanoma patients, and that FOXP3low naive Tregs and FOXP3low non-Tregs increased as the stage progressed (8).